Impax Asset Management Group plc bought a new stake in HCA Healthcare, Inc. (NYSE:HCA – Free Report) in the 3rd quarter, Holdings Channel reports. The firm bought 4,793 shares of the company’s stock, valued at approximately $2,045,000.
Other institutional investors have also added to or reduced their stakes in the company. MidFirst Bank acquired a new stake in HCA Healthcare in the second quarter valued at $28,000. Clearstead Trust LLC acquired a new position in shares of HCA Healthcare during the 2nd quarter worth about $29,000. Latitude Advisors LLC bought a new stake in shares of HCA Healthcare in the 3rd quarter valued at about $32,000. Delos Wealth Advisors LLC bought a new stake in shares of HCA Healthcare in the 2nd quarter valued at about $35,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in HCA Healthcare in the 3rd quarter valued at about $40,000. 62.73% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, COO Jon Foster sold 21,713 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $494.95, for a total value of $10,746,849.35. Following the transaction, the chief operating officer owned 10,000 shares of the company’s stock, valued at approximately $4,949,500. This represents a 68.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Schlosser sold 1,200 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $494.65, for a total value of $593,580.00. Following the transaction, the executive vice president owned 1,443 shares in the company, valued at approximately $713,779.95. This trade represents a 45.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 36,413 shares of company stock valued at $18,251,464. 1.50% of the stock is owned by insiders.
HCA Healthcare Stock Performance
NYSE HCA opened at $475.84 on Thursday. The stock has a market cap of $99.40 billion, a PE ratio of 15.77, a P/E/G ratio of 1.67 and a beta of 1.11. The firm has a 50-day moving average of $457.97 and a 200-day moving average of $446.05. HCA Healthcare, Inc. has a 52-week low of $353.99 and a 52-week high of $556.52.
HCA Healthcare (NYSE:HCA – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $7.22 EPS for the quarter, beating analysts’ consensus estimates of $6.65 by $0.57. The business had revenue of $19.85 billion for the quarter, compared to analyst estimates of $19.33 billion. HCA Healthcare had a net margin of 8.61% and a negative return on equity of 198.52%. HCA Healthcare’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.96 EPS. As a group, analysts predict that HCA Healthcare, Inc. will post 30.14 EPS for the current fiscal year.
HCA Healthcare Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 29th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.78 per share. This represents a $3.12 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Tuesday, December 15th. HCA Healthcare’s payout ratio is currently 10.34%.
Analysts Set New Price Targets
A number of equities analysts recently commented on HCA shares. BMO Capital Markets began coverage on HCA Healthcare in a report on Tuesday, September 22nd. They set an “outperform” rating and a $495.00 price target for the company. JPMorgan Chase & Co. upped their price objective on HCA Healthcare from $425.00 to $475.00 and gave the company a “neutral” rating in a research note on Wednesday. The Goldman Sachs Group reduced their target price on HCA Healthcare from $558.00 to $485.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Weiss Ratings raised HCA Healthcare from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, November 10th. Finally, Robert W. Baird increased their price target on HCA Healthcare from $393.00 to $409.00 and gave the company a “neutral” rating in a research note on Wednesday, October 28th. Sixteen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, HCA Healthcare currently has an average rating of “Moderate Buy” and a consensus target price of $482.30.
Read Our Latest Stock Analysis on HCA
HCA Healthcare Profile
HCA Healthcare is a healthcare services company that operates hospitals and other care facilities. Its services include inpatient and outpatient care, emergency treatment, surgery, diagnostic services and specialized care across areas such as cancer and cardiovascular medicine. The company serves patients in the United States and the United Kingdom through its network of hospitals and outpatient facilities, including surgery centers, urgent care clinics and physician practices. Founded in 1968, HCA Healthcare is headquartered in Nashville, Tennessee.
Further Reading
- Five stocks we like better than HCA Healthcare
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA – Free Report).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
